GlassScriptPhysician profile
Christopher L Po
NPI 1679665608
$4,650.59
in general payments reported to CMS, 2019-2025
31 companies · $1,806 in 2025
The $1,806 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $21.44 · 2021: $186 · 2022: $594 · 2023: $679 · 2024: $1,073 · 2025: $1,806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,520 · Education: $38.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,519.59 |
| Education | $38.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $558.93 | 2021-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $479.64 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $448.41 | 2019-2025 | Airsupra, Farxiga |
| Calliditas Therapeutics US INC. | $430.79 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $422.15 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $267.35 | 2024-2025 | Tavneos, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $234.42 | 2021-2025 | |
| Glaxosmithkline, LLC. | $186.61 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Ani Pharmaceuticals, INC. | $179.82 | 2022-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $157.24 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Travere Therapeutics, INC. | $150.70 | 2022-2025 | |
| Ardelyx, INC. | $129.11 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $114.42 | 2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $110.93 | 2023 | Quviviq |
| Pfizer INC. | $106.22 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $87.32 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $83.65 | 2019-2025 | Velphoro |
| Exact Sciences Corporation | $69.39 | 2024-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.08 | 2024-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.71 | 2024-2025 | Caplyta |
| Novo Nordisk INC | $66.24 | 2025 | Ozempic, Wegovy, Rybelsus |
| Vifor Pharma, INC. | $39.79 | 2020-2022 | |
| Corcept Therapeutics | $39.39 | 2025 | Korlym |
| Dexcom, INC. | $24.96 | 2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $23.92 | 2025 | Freestyle Libre 3 |
| Phadia US INC. | $23.39 | 2025 | Immunocap |
| Daiichi Sankyo INC. | $21.66 | 2022 | |
| Apellis Pharmaceuticals, INC. | $17.12 | 2025 | Empaveli |
| Gilead Sciences, INC. | $15.09 | 2021 | |
| Medtronic, INC. | $14.45 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Po listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.